Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1951 2
1952 4
1953 3
1955 2
1960 1
1963 1
1993 2
1994 5
1995 7
1996 8
1997 44
1998 32
1999 53
2000 86
2001 98
2002 120
2003 127
2004 178
2005 163
2006 181
2007 185
2008 210
2009 200
2010 213
2011 214
2012 210
2013 220
2014 214
2015 276
2016 274
2017 301
2018 324
2019 389
2020 497
2021 533
2022 46
Text availability
Article attribute
Article type
Publication date

Search Results

4,876 results
Results by year
Filters applied: . Clear all
Page 1
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF.
Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Docherty KF, et al. JACC Heart Fail. 2020 Oct;8(10):800-810. doi: 10.1016/j.jchf.2020.06.020. JACC Heart Fail. 2020. PMID: 33004114 Free article. Review.
This paper reviews the current understanding of the effects of sacubitril/valsartan and highlights expected developments over the next 5 years, including potential new indications for use. Additionally, a practical, evidence-based approach is provided to the clinical integ …
This paper reviews the current understanding of the effects of sacubitril/valsartan and highlights expected developments over the nex …
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray JJV. Solomon SD, et al. JACC Heart Fail. 2017 Jul;5(7):471-482. doi: 10.1016/j.jchf.2017.04.013. Epub 2017 Jun 26. JACC Heart Fail. 2017. PMID: 28662936 Free article. Review.
OBJECTIVES: The PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) trial is designed to determine the efficacy and safety of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan compared with valsart
OBJECTIVES: The PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) trial is designe …
Antihypertensive effect of sacubitril/valsartan: a meta-analysis.
De Vecchis R, Ariano C, Soreca S. De Vecchis R, et al. Minerva Cardioangiol. 2019 Jun;67(3):214-222. doi: 10.23736/S0026-4725.19.04869-2. Epub 2019 Mar 18. Minerva Cardioangiol. 2019. PMID: 30895762 Review.
INTRODUCTION: The efficacy and safety of sacubitril/valsartan used as an antihypertensive agent has not yet been completely assessed. ...In all studies, the comparator drug was an angiotensin receptor blocker (ARB) - valsartan in two cases and olmesartan in the rema …
INTRODUCTION: The efficacy and safety of sacubitril/valsartan used as an antihypertensive agent has not yet been completely assessed. …
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD. Seferovic JP, et al. Lancet Diabetes Endocrinol. 2017 May;5(5):333-340. doi: 10.1016/S2213-8587(17)30087-6. Epub 2017 Mar 18. Lancet Diabetes Endocrinol. 2017. PMID: 28330649 Free PMC article. Clinical Trial.
Similarly, fewer patients were started on oral antihyperglycaemic therapy (077, 058-102, p=0073) in the sacubitril/valsartan group. INTERPRETATION: Patients with diabetes and HFrEF enrolled in PARADIGM-HF who received sacubitril/valsartan had a greater long-term red …
Similarly, fewer patients were started on oral antihyperglycaemic therapy (077, 058-102, p=0073) in the sacubitril/valsartan group. I …
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer N, Vardeny O, Claggett B, Jhund PS, Solomon SD. McMurray JJV, et al. Circulation. 2020 Feb 4;141(5):338-351. doi: 10.1161/CIRCULATIONAHA.119.044491. Epub 2019 Nov 17. Circulation. 2020. PMID: 31736337
The benefit from sacubitril-valsartan was attributable to reduction in heart failure hospitalization. ...The difference in adverse events between sacubitril-valsartan and valsartan was similar in women and men. CONCLUSIONS: As compared with valsartan, …
The benefit from sacubitril-valsartan was attributable to reduction in heart failure hospitalization. ...The difference in adverse ev …
Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Lee YH, Lin PL, Chiou WR, Huang JL, Lin WY, Liao CT, Chung FP, Liang HW, Hsu CY, Chang HY. Lee YH, et al. ESC Heart Fail. 2021 Apr;8(2):1204-1215. doi: 10.1002/ehf2.13182. Epub 2021 Jan 6. ESC Heart Fail. 2021. PMID: 33410280 Free PMC article.
AIMS: Ivabradine and sacubitril/valsartan are second-line therapies for patients with heart failure and reduced ejection fraction (HFrEF) based on guideline recommendations. ...Patients were classified into (1) Simultaneous group: simultaneous prescription of ivabradine an …
AIMS: Ivabradine and sacubitril/valsartan are second-line therapies for patients with heart failure and reduced ejection fraction (HF …
Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial.
Berg DD, Braunwald E, DeVore AD, Lala A, Pinney SP, Duffy CI, Gurmu Y, Velazquez EJ, Morrow DA. Berg DD, et al. JACC Heart Fail. 2020 Oct;8(10):834-843. doi: 10.1016/j.jchf.2020.06.008. Epub 2020 Aug 12. JACC Heart Fail. 2020. PMID: 32800511 Free PMC article. Clinical Trial.
OBJECTIVES: This study sought to evaluate the efficacy and safety of sacubitril/valsartan according to dose level achieved in the PIONEER-HF (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failur …
OBJECTIVES: This study sought to evaluate the efficacy and safety of sacubitril/valsartan according to dose level achieved in the PIO …
Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction.
Suzuki K, Claggett B, Minamisawa M, Nochioka K, Mitchell GF, Anand IS, Zannad F, Shah SJ, Lefkowitz M, Shi V, Pfeffer MA, McMurray JJV, Solomon SD. Suzuki K, et al. Hypertension. 2021 Feb;77(2):546-556. doi: 10.1161/HYPERTENSIONAHA.120.16277. Epub 2020 Dec 28. Hypertension. 2021. PMID: 33356401 Clinical Trial.
One year after randomization, PP was significantly lower in the sacubitril/valsartan group compared with the valsartan group (3.0 mm Hg decrease [95% CI, 2.4-3.5]; P<0.001). In conclusion, PP was an independent predictor of cardiovascular events in patients with …
One year after randomization, PP was significantly lower in the sacubitril/valsartan group compared with the valsartan group ( …
Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
Khan MS, Felker GM, Piña IL, Camacho A, Bapat D, Ibrahim NE, Maisel AS, Prescott MF, Ward JH, Solomon SD, Januzzi JL, Butler J. Khan MS, et al. JACC Heart Fail. 2021 Feb;9(2):137-145. doi: 10.1016/j.jchf.2020.09.014. Epub 2020 Dec 9. JACC Heart Fail. 2021. PMID: 33309581 Free article.
OBJECTIVE: This study sought to determine whether patients with heart failure and reduced ejection fraction (HFrEF) with type 2 diabetes mellitus (T2DM) have similar reverse cardiac remodeling with sacubitril/valsartan as patients without T2DM. BACKGROUND: Sacubitril/va
OBJECTIVE: This study sought to determine whether patients with heart failure and reduced ejection fraction (HFrEF) with type 2 diabetes mel …
Entresto, a New Panacea for Heart Failure?
Khalil P, Kabbach G, Said S, Mukherjee D. Khalil P, et al. Cardiovasc Hematol Agents Med Chem. 2018;16(1):5-11. doi: 10.2174/1871525716666180313121954. Cardiovasc Hematol Agents Med Chem. 2018. PMID: 29532764 Review.
Recently, the Food and Drug Administration (FDA) approved a drug with brand name Entresto (Sacubitril/Valsartan or LCZ696), an angiotensin receptor neprilysin inhibitor for the use in Heart Failure with Reduced Ejection Fraction (HFrEF) patients instead of ACEI's and ARBs. …
Recently, the Food and Drug Administration (FDA) approved a drug with brand name Entresto (Sacubitril/Valsartan or LCZ696), an angiot …
4,876 results